Loss of IFN-γ pathway genes in tumor cells as a mechanism of resistance to anti-CTLA-4 therapy

Gao, Jianjun, Shi, Lewis Zhichang, Zhao, Hao, Chen, Jianfeng, Xiong, Liangwen, He, Qiuming, Chen, Tenghui, Roszik, Jason +8 more·2016·Cell

DOI 10.1016/j.cell.2016.08.069

Cited by (1,000)

Items 401–500 of 1,000

Inhibition of MAN2A1 Enhances the Immune Response to Anti–PD-L1 in Human Tumors
Sailing Shi, Shengqing Stan Gu, Tong Han, Wubing Zhang, Lei Huang, Ziyi Li, Deng Pan, Jingxin Fu, Jun Ge, Myles A Brown et al. · 2020 · Clinical Cancer Research
Immunotherapy in Breast Cancer: When, How, and What Challenges?
Beatriz Henriques, Fernando Mendes, Diana F. Martins · 2021 · Biomedicines
Inhibition of IL-17A Protects against Thyroid Immune-Related Adverse Events while Preserving Checkpoint Inhibitor Antitumor Efficacy
Melissa G. Lechner, Anushi Y. Patel, Willy Hugo, Trevor E. Angell, Mandy I. Cheng, Marissa S. Pioso, Aline T. Hoang, Natalie Yakobian, Ethan C. McCarthy, Ho-Chung Chen et al. · 2022 · The Journal of Immunology
Immuno-oncology-101: overview of major concepts and translational perspectives
Bertrand Allard, Sandrine Aspeslagh, Soizic Garaud, Floriane Dupont, Cinzia Solinas, Marleen Kok, Bertrand Routy, Christos P. Sotiriou, John Stagg, Laurence Buisseret · 2018 · Seminars in Cancer Biology
Machine learning reveals a PD-L1–independent prediction of response to immunotherapy of non-small cell lung cancer by gene expression context
Marcel Wiesweg, Fabian Dominik Mairinger, Henning Reis, Moritz Goetz, Jens Kollmeier, Daniel Misch, Susann Stephan-Falkenau, Thomas Mairinger, Robert F. H. Walter, Thomas Hager et al. · 2020 · European Journal of Cancer
Prediction of Immunotherapy Response in Melanoma through Combined Modeling of Neoantigen Burden and Immune-Related Resistance Mechanisms
Charles W. Abbott, Sean M. Boyle, Rachel Marty Pyke, Lee McDaniel, Éric Levy, Fábio C. P. Navarro, Dattatreya Mellacheruvu, Simo V. Zhang, Mengyao Tan, Rose Santiago et al. · 2021 · Clinical Cancer Research
Checkpoint immunotherapy in pediatrics: here, gone, and back again
Long, Adrienne H., Morgenstern, Daniel A., Leruste, Amaury, Bourdeaut, Franck, Davis, Kara L. · 2022 · American Society of Clinical Oncology Educational Book
Distinct Mutation Patterns Reveal Melanoma Subtypes and Influence Immunotherapy Response in Advanced Melanoma Patients
Franz J. Hilke, Tobias W. Sinnberg, Axel Gschwind, Heike Niessner, German M. Demidov, Teresa Maria Santos Amaral, Stephan Ossowski, Irina Bonzheim, Martin Röcken, Olaf Rieß et al. · 2020 · Cancers
Molecular Mechanism of the Anti-Inflammatory Action of Heparin
L. Litov, P. Petkov, Miroslav Angelov Rangelov, Nevena Ilieva, Elena Lilkova, Nadezhda Hristova Todorova, Elena Krachmarova, Kristina Malinova, Anastas G. Gospodinov, Rossitsa H. Hristova et al. · 2021 · International Journal of Molecular Sciences
The multi-molecular mechanisms of tumor-targeted drug resistance in precision medicine
Xinming Li, Mingdong Li, Meiying Huang, Qianyi Lin, Qiuping Fang, Jianjiang Liu, Xiaohui Chen, Lin Liu, Xuliang Zhan, Huisi Shan et al. · 2022 · Biomedicine & Pharmacotherapy
SOCS1 is a critical checkpoint in immune homeostasis, inflammation and tumor immunity
Grace M. Bidgood, Narelle Keating, Karen Doggett, Sandra E. Nicholson · 2024 · Frontiers in Immunology
Anlotinib potentiates anti‐PD1 immunotherapy via transferrin receptor‐dependent CD8 + T‐cell infiltration in hepatocellular carcinoma
Fei Song, Bo Hu, Xiao‐Liang Liang, Jian‐Wen Cheng, Chenggui Wang, Pengxiang Wang, Tianlun Wang, Peng‐Ju Tang, Haixiang Sun, Wei Guo et al. · 2024 · Clinical and Translational Medicine
Androgen Receptor Inhibition Increases MHC Class I Expression and Improves Immune Response in Prostate Cancer
Lisa N. Chesner, Fanny Polesso, Julie Nicole Graff, Jessica E. Hawley, Alexis K. Smith, Arian Lundberg, Rajdeep Das, Tanushree Shenoy, Martin Sjöström, Faming Zhao et al. · 2024 · Cancer Discovery
Dual role of interferon-gamma in the response of melanoma patients to immunotherapy with immune checkpoint inhibitors
Piotr Wawrzyniak, Mariusz L. Hartman · 2025 · Molecular Cancer
Immunotherapy in pancreatic cancer: Unleash its potential through novel combinations
Songchuan Guo, Merly Contratto, George Miller, Lawrence Leichman, Jennifer J. Wu · 2017 · World Journal of Clinical Oncology
Trial Watch: Immunostimulation with recombinant cytokines for cancer therapy
Elena García-Martínez, Melody M. Smith, Aitziber Buqué, Fernando Aranda, Francisco Ayala de la Peña, Alejandra Ivars Rubio, Manuel Sánchez Cánovas, M.A. Vicente Conesa, Jitka Palich Fucikova, Radek Špíšek et al. · 2018 · OncoImmunology
Resistance to immune checkpoint inhibitors in advanced gastro-oesophageal cancers
Mark A Baxter, Fearghas Middleton, Hannah P. Cagney, Russell Petty · 2021 · British Journal of Cancer
Regulation of the antigen presentation machinery in cancer and its implication for immune surveillance
Adithya Balasubramanian, Thomas John, Marie-Liesse Asselin-Labat · 2022 · Biochemical Society Transactions
Targeting tumour-reprogrammed myeloid cells: the new battleground in cancer immunotherapy
Francesco De Sanctis, Annalisa Adamo, Stefania Canè, Stefano Ugel · 2022 · Seminars in Immunopathology
Current Landscape of Cancer Immunotherapy: Harnessing the Immune Arsenal to Overcome Immune Evasion
Ankita Mitra, Anoop Kumar, Nitin Purushottam Amdare, Rajiv Pathak · 2024 · Biology
Combination of IAP antagonist and IFNγ activates novel caspase-10- and RIPK1-dependent cell death pathways
Maria C. Tanzer, Nufail R. Khan, James A. Rickard, Nima Etemadi, Najoua Lalaoui, Sukhdeep Kaur Spall, Joanne M. Hildebrand, David Segal, Maria Miasari, Diep Chau et al. · 2017 · Cell Death and Differentiation
A Mechanism of Resistance to Antibody-Targeted Immune Attack
Dalal S. Aldeghaither, David J. Zahavi, Joseph Christopher Murray, Elana Judith Fertig, Garrett T. Graham, Yongwei Zhang, Allison O’Connell, Junfeng Ma, Sandra A. Jablonski, Louis M. Weiner · 2018 · Cancer Immunology Research
Cold and heterogeneous T cell repertoire is associated with copy number aberrations and loss of immune genes in small-cell lung cancer
Ming Chen, Runzhe Chen, Ying Jin, Jun Li, Xin Yang Hu, Jiexin Zhang, Junya Fujimoto, Shawna Marie Hubert, Carl Michael Gay, Bo Zhu et al. · 2021 · Nature Communications
PD1 Blockade Enhances ICAM1-Directed CAR T Therapeutic Efficacy in Advanced Thyroid Cancer
Katherine D. Gray, Jaclyn E. McCloskey, Yogindra Vedvyas, Olivia R. Kalloo, Steve El Eshaky, Yanping Yang, Enda Shevlin, Marjan Zaman, Timothy M. Ullmann, Heng Liang et al. · 2020 · Clinical Cancer Research
NAT10/ac4C/JunB facilitates TNBC malignant progression and immunosuppression by driving glycolysis addiction
Guozheng Li, Xin Ma, Shiyao Sui, Yihai Chen, Hui Li, Lei Liu, Xin Zhang, Lei Zhang, Yi Hao, Zihan Yang et al. · 2024 · Journal of Experimental & Clinical Cancer Research
Immune surveillance in melanoma: From immune attack to melanoma escape and even counterattack
Fade Aziz Mahmoud, Bradley D. Shields, Issam Makhoul, Nathan L. Avaritt, Henry K. Wong, Laura Fulper Hutchins, Sara C. Shalin, Alan J. Tackett · 2017 · Cancer Biology & Therapy
Immune Checkpoint Inhibitors in the Treatment of Melanoma: From Basic Science to Clinical Application
Surface Oncology, 50 Hampshire Street, 8th Floor, Cambridge, MA 02139, USA, Matthew P. Rausch, Karen Taraszka Hastings · 2017 · Codon Publications eBooks
Modulation of the tumor micro-environment by CD8+ T cell-derived cytokines
Mirjam E. Hoekstra, Saskia V Vijver, Ton N. Schumacher · 2021 · Current Opinion in Immunology
Translating the evolving molecular landscape of tumors to biomarkers of response for cancer immunotherapy
Valsamo Anagnostou, Blair V. Landon, Jamie E. Medina, Patrick M. Forde, Victor E. Velculescu · 2022 · Science Translational Medicine
Phase II trial of neoadjuvant sitravatinib plus nivolumab in patients undergoing nephrectomy for locally advanced clear cell renal cell carcinoma
Jose Antonio Karam, Pavlos Msaouel, Cara Haymaker, Surena F. Matin, Matthew T. Campbell, Amado J. Zurita, Amishi Yogesh Shah, Ignacio Ivan Wistuba, Enrica Marmonti, Dzifa Y. Duose et al. · 2023 · Nature Communications
Clonally expanded, thyrotoxic effector CD8 + T cells driven by IL-21 contribute to checkpoint inhibitor thyroiditis
Melissa G. Lechner, Zikang Zhou, Aline T. Hoang, Nicole Huang, Jessica Ortega, Lauren N Scott, Ho-Chung Chen, Anushi Y. Patel, Rana Yakhshi Tafti, Kristy Kim et al. · 2023 · Science Translational Medicine
Unraveling resistance to immunotherapy in MSI-high colorectal cancer
Heregger, Ronald, Huemer, Florian, Steiner, Markus, Gonzalez-Martinez, Alejandra, Greil, Richard, Weiss, Lukas · 2023 · Cancers
Immunotherapy of MSI Cancer: Facts and Hopes
Helen Catherine Wilbur, Dung Thi Le, Parul Agarwal · 2023 · Clinical Cancer Research
Acquired resistance to cancer immunotherapy
Arianna Draghi, Christopher Aled Chamberlain, Andrew J.S. Furness, Marco Donia · 2018 · Seminars in Immunopathology
Immunosuppressive circuits in tumor microenvironment and their influence on cancer treatment efficacy
Alessandra Tuccitto, Eriomina Shahaj, Elisabetta Vergani, Simona Ferro, Veronica Huber, Monica Rodolfo, Chiara Castelli, Licia Rivoltini, Viviana Vallacchi · 2018 · Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin
Recent Advances in Polymeric Nanomedicines for Cancer Immunotherapy
Eun Sook Lee, Jung Min Shin, Soyoung Son, Hyewon Ko, Wooram Um, Seok Ho Song, Jae Ah Lee, Jae Hyung Park · 2019 · Advanced Healthcare Materials
T cell costimulation, checkpoint inhibitors and anti-tumor therapy
Dipankar Nandi, Sanmoy Pathak, Taru Verma, Madhulika Singh, Avik Chattopadhyay, Samriddhi Thakur, Abinaya Raghavan, Abhijeet Gokhroo, Vijayamahantesh Vijayamahantesh · 2020 · Journal of Biosciences
A novel scoring method based on RNA‐Seq immunograms describing individual cancer‐immunity interactions
Yukari Kobayashi, Yoshihiro Kushihara, Noriyuki Saito, Shigeo Yamaguchi, Kazuhiro Kakimi · 2020 · Cancer Science
Paired whole exome and transcriptome analyses for the Immunogenomic changes during concurrent chemoradiotherapy in esophageal squamous cell carcinoma
Sehhoon Park, Je‐Gun Joung, Yang Won Min, Jae‐Yong Nam, Daeun Ryu, Dongryul Oh, Woong‐Yang Park, Se Kyung Lee, Yoon‐La Choi, Jin Seok Ahn et al. · 2019 · Journal for ImmunoTherapy of Cancer
Macrophage and monocyte subsets as new therapeutic targets in cancer immunotherapy
Birgit Fendl, Anna Sophie Berghoff, Matthias Preusser, B. Maier · 2023 · ESMO Open
Primary and Acquired Resistance to Immunotherapy with Checkpoint Inhibitors in NSCLC: From Bedside to Bench and Back
Annapaola Mariniello, Maxime Borgeaud, MARC H. WEINER, Daniele Frisone, Floryane Kim, Alfredo Addeo · 2025 · BioDrugs
Mechanisms of Primary and Secondary Resistance to Immune Checkpoint Inhibitors in Cancer
Tiffany Seto, Danny L. Sam, Minggui Pan · 2019 · Medical Sciences
Identification and Utilization of Biomarkers to Predict Response to Immune Checkpoint Inhibitors
Ole V. Gjoerup, Charlotte A. Brown, Jeffrey S. Ross, Richard S.P. Huang, Alexa Betzig Schrock, James Creeden, David A. Fabrizio, Khaled A. Tolba · 2020 · The AAPS Journal
Personalizing neoadjuvant immune-checkpoint inhibition in patients with melanoma
Lucas, Minke W., Versluis, Judith M., Rozeman, Elisa A., Blank, Christian U. · 2023 · Nature Reviews Clinical Oncology
LincRNA-immunity landscape analysis identifies EPIC1 as a regulator of tumor immune evasion and immunotherapy resistance
Weiwei Guo, Yue Wang, Min Yang, Zehua Wang, Yifei Wang, Smriti Chaurasia, Zhiyuan Wu, Min Zhang, Ghanshyam Singh Yadav, Sanjay Rathod et al. · 2021 · Science Advances
The paradox of immune checkpoint inhibition re-activating tuberculosis
Mohamed I. M. Ahmed, Liku B. Tezera, Paul T. Elkington, Alasdair J. Leslie · 2022 · European Respiratory Journal
Enhancer decommissioning by MLL4 ablation elicits dsRNA-interferon signaling and GSDMD-mediated pyroptosis to potentiate anti-tumor immunity
Hanhan Ning, SHAN HU HUANG, Lei Yang, Renyong Zhi, Han Yan, Jiaxing Jin, Zhenyu Hu, Kaimin Guo, Jinhua Liu, Jie Yang et al. · 2022 · Nature Communications
Defects in antigen processing and presentation: mechanisms, immune evasion and implications for cancer vaccine development
Florian Huber, Michal Bassani‐Sternberg · 2025 · Nature reviews. Immunology
Catch and Release of Cytokines Mediated by Tumor Phosphatidylserine Converts Transient Exposure into Long-Lived Inflammation
Jennifer E. Oyler, Alon Oyler‐Yaniv, Mojdeh Shakiba, Nina Min, Ying-Han Chen, Sheue-yann Cheng, Oleg Krichevsky, Nihal Altan‐Bonnet, Grégoire Y Altan-Bonnet · 2017 · Molecular Cell
Inhibition of SRC family kinases facilitates anti-CTLA4 immunotherapy in head and neck squamous cell carcinoma
Guang‐Tao Yu, Liang Mao, Lei Wu, Wei‐Wei Deng, Lin‐Lin Bu, Jianfeng Liu, Lei Chen, Leilei Yang, Hao Wu, Wen‐Feng Zhang et al. · 2018 · Cellular and Molecular Life Sciences
How Tumor Cell Dedifferentiation Drives Immune Evasion and Resistance to Immunotherapy
Jinyang Li, Ben Z. Stanger · 2020 · Cancer Research
Screening of organoids derived from patients with breast cancer implicates the repressor NCOR2 in cytotoxic stress response and antitumor immunity
Kelvin K. Tsai, Shenq‐Shyang Huang, Jason J. Northey, Wen‐Ying Liao, Chung‐Chi Hsu, Li‐Hsin Cheng, Michael Edward Werner, Chih‐Pin Chuu, Chandrima Chatterjee, Jonathon N. Lakins et al. · 2022 · Nature Cancer
Tumor-intrinsic response to IFNγ shapes the tumor microenvironment and anti–PD-1 response in NSCLC
Bonnie Bullock, Abigail K. Kimball, Joanna M. Poczobutt, Alexander J. Neuwelt, Howard Y. Li, Amber M. Johnson, Jeff Kwak, Emily K. Kleczko, Rachael E. Kaspar, Emily K Wagner et al. · 2019 · Life Science Alliance
The role of CD4+ T cells in tumor and chronic viral immune responses
Luoyingzi Xie, Jingyi Fang, Juncheng Yu, Weinan Zhang, Zhiqiang He, Lilin Ye, Huaizhi Wang · 2023 · MedComm
Platinum-resistance in epithelial ovarian cancer: an interplay of epithelial–mesenchymal transition interlinked with reprogrammed metabolism
Dilys T.H. Leung, Zoe K. Price, Noor A. Lokman, Wanqi Wang, Lizamarie Goonetilleke, Elif Kadife, Martin Klaus Oehler, Carmela Ricciardelli, George Kannourakis, Nuzhat Ahmed · 2022 · Journal of Translational Medicine
Possible Biomarkers for Cancer Immunotherapy
Takehiro Otoshi, Tatsuya Nagano, Motoko Yoshikawa TACHIHARA, Yoshihiro Nishimura · 2019 · Cancers
Combination of STING and TLR 7/8 Agonists as Vaccine Adjuvants for Cancer Immunotherapy
Shubhmita Bhatnagar, Vishnu Revuri, Manan Shah, Peter G. Larson, Zekun Shao, Daohai Yu, Swayam Prabha, Thomas S. Griffith, David M. Ferguson, Jayanth Panyam · 2022 · Cancers
NIR-Responsive Photodynamic Nanosystem Combined with Antitumor Immune Optogenetics Bacteria for Precise Synergetic Therapy
Changsong Wu, Meihui Cui, Li Cai, Chen Chen, Xiaohui Zhu, Yihan Wu, Jinliang Liu, Hanjie Wang, Yong Zhang · 2022 · ACS Applied Materials & Interfaces
Cancer Cell Phenotype Plasticity as a Driver of Immune Escape in Melanoma
Valentin Benboubker, Félix Boivin, Stéphane Dalle, Julie Caramel · 2022 · Frontiers in Immunology
Dissecting the tumor microenvironment in response to immune checkpoint inhibitors via single-cell and spatial transcriptomics
Wendi Liu, Anusha Puri, Doris Fu, Lee Chen, Cassia Wang, M Kellis, Jiekun Yang · 2023 · Clinical & Experimental Metastasis
Overcoming cancer therapy resistance: From drug innovation to therapeutics
Jinrui Wei, Meng‐Yi Lu, Tian‐Hua Wei, Joshua S. Fleishman, Hui Juan Yu, Xiao-Li Chen, Xiang-Tu Kong, Shan‐Liang Sun, Nian‐Guang Li, Ye Yang et al. · 2025 · Drug Resistance Updates
Single-cell profiling of dynamic cytokine secretion and the phenotype of immune cells
Xingyue An, Victor G. Sendra, Ivan Liadi, Balakrishnan Ramesh, Gabrielle Romain, Cara Haymaker, Melisa A. Martinez-Paniagua, Yanbin Lu, Laszlo George Radvanyi, Badrinath Roysam et al. · 2017 · PLoS ONE
Progresses and Perspectives of Anti-PD-1/PD-L1 Antibody Therapy in Head and Neck Cancers
Bo Yang, Tingjun Liu, Yang Qu, Hangbo Liu, Song Guo Zheng, Bin Cheng, Jianbo Sun · 2018 · Frontiers in Oncology
Mechanism and potential predictive biomarkers of immune checkpoint inhibitors in NSCLC
Jialin Qu, Man Jiang, Li Wang, Deze Zhao, Kang Qin, Yun Wang, Junyan Tao, Xiaochun Zhang · 2020 · Biomedicine & Pharmacotherapy
Wedding of Molecular Alterations and Immune Checkpoint Blockade: Genomics as a Matchmaker
Elena Fountzilas, Razelle Kurzrock, Henry Hiep Vo, Apostolia Maria Tsimberidou · 2021 · JNCI Journal of the National Cancer Institute
Effect of NCOR1 Mutations on Immune Microenvironment and Efficacy of Immune Checkpoint Inhibitors in Patient with Bladder Cancer
Anqi Lin, Zhengang Qiu, Jian Zhang, Peng Luo · 2021 · Frontiers in Immunology
Resistance to immune checkpoint blockade: Mechanisms, counter-acting approaches, and future directions
Alexander F. Haddad, Jacob S. Young, Sabraj A. Gill, Manish Kumar Aghi · 2022 · Seminars in Cancer Biology
From complexity to clarity: unravelling tumor heterogeneity through the lens of tumor microenvironment for innovative cancer therapy
Sikiru Opeyemi Imodoye, Kamoru Ademola Adedokun, Ibrahim Olajide Bello · 2024 · Histochemistry and Cell Biology
SLFN11 can sensitize tumor cells towards IFN-γ-mediated T cell killing
Riccardo Mezzadra, Marjolein J. W. de Bruijn, Lucas T. Jae, Raquel Gomez, Anja M. Duursma, Ferenc A. Scheeren, Thijn R. Brummelkamp, Ton N. Schumacher · 2019 · PLoS ONE
Current status and future perspectives of immunotherapy in bladder cancer treatment
Zhangsong Wu, Jinjian Liu, Ruixiang Dai, Song Wu · 2020 · Science China Life Sciences
IFN-γ activates the tumor cell-intrinsic STING pathway through the induction of DNA damage and cytosolic dsDNA formation
Hui Xiong, Yu Xi, Zhiwei Yuan, Boyu Wang, Shaojie Hu, Can Fang, Yixin Cai, Xiangning Fu, Lequn Li · 2022 · OncoImmunology
Tumor-associated macrophage clusters linked to immunotherapy in a pan-cancer census
Chen Wei, Yijie Ma, Mengyu Wang, Siyi Wang, Wenyue Yu, Shuailei Dong, Wenying Deng, Liangyu Bie, Chi Zhang, Wei Shen et al. · 2024 · npj Precision Oncology
Nuclear IRF-1 expression as a mechanism to assess “Capability” to express PD-L1 and response to PD-1 therapy in metastatic melanoma
James William Smithy, Lauren M. Moore, Vasiliki Pelekanou, Jamaal Rehman, Patricia Gaule, Pok Fai Wong, Veronique M. Neumeister, Mario Sznol, Harriet M. Kluger, David L. Rimm · 2017 · Journal for ImmunoTherapy of Cancer
Decreased IFIT2 Expression Promotes Gastric Cancer Progression and Predicts Poor Prognosis of the Patients
Lujun Chen, Wensi Zhai, Xiao Wei Zheng, Quanqin Xie, Qi Zhou, Min Tao, Yibei Zhu, Changping Wu, Jingting Jiang · 2017 · Cellular Physiology and Biochemistry
TEIPP antigens for T-cell based immunotherapy of immune-edited HLA class Ilow cancers
Koen A. Marijt, Elien M. Doorduijn, Thorbald van Hall · 2018 · Molecular Immunology
Determinants of Resistance to Checkpoint Inhibitors
Linda L. Tran, Dan Theodorescu · 2020 · International Journal of Molecular Sciences
IFNγ Signaling in Natural and Therapy-Induced Antitumor Responses
A. Martínez, Enrique Javier Arenas, Joaquı́n Arribas · 2021 · Clinical Cancer Research
Future of immune checkpoint inhibitors: focus on tumor immune microenvironment
Yunlong Jia, Lihua Liu, Baoen Shan · 2020 · Annals of Translational Medicine
Reprogramming NK Cells and Macrophages via Combined Antibody and Cytokine Therapy Primes Tumors for Elimination by Checkpoint Blockade
Chensu Wang, Ang Cui, Maurice Bukenya, Aereas Aung, Dikshant Pradhan, Charles A. Whittaker, Yash Agarwal, Ayush Thomas, Simon Liang, Parastoo Amlashi et al. · 2021 · Cell Reports
IFN-γ and TGF-β, Crucial Players in Immune Responses: A Tribute to Howard Young
Thierry Gauthier, WanJun Chen · 2022 · Journal of Interferon & Cytokine Research
Genomic instability as a driver and suppressor of anti-tumor immunity
Marta Requesens, Floris Foijer, Hans W. Nijman, Marco de Bruyn · 2024 · Frontiers in Immunology
Molecular and Genomic Determinants of Response to Immune Checkpoint Inhibition in Cancer
Russell William Jenkins, Rohit Thummalapalli, Jacob Carter, Israel Cañadas, David Allen Barbie · 2017 · Annual Review of Medicine
Checkpoint inhibitors in melanoma and early phase development in solid tumors: what’s the future?
Paolo A. Ascierto, Grant A. McArthur · 2017 · Journal of Translational Medicine
Interferon‐induced protein 35 inhibits endothelial cell proliferation, migration and re‐endothelialization of injured arteries by inhibiting the nuclear factor‐kappa B pathway
Dongdong Jian, Weiwei Wang, X. Zhou, Zhuyin Jia, J. Wang, Min Yang, Wenhe Zhao, Z. Jiang, Xiao Hu, Jianhua Zhu · 2018 · Acta Physiologica
Immunologic and immunogenomic aspects of tumor progression
Andrea Ladányi, József Tı́már · 2019 · Seminars in Cancer Biology
Biological Factors behind Melanoma Response to Immune Checkpoint Inhibitors
Magdalena Olbryt, Marcin Rajczykowski, Wiesława Widłak · 2020 · International Journal of Molecular Sciences
Chimeric antigen receptor engineered NK cellular immunotherapy overcomes the selection of T-cell escape variant cancer cells
Maxwell Y Lee, Yvette L. Robbins, Cem M. Sievers, Jay Friedman, Houssein Abdul Sater, Paúl E. Clavijo, Nancy P. Judd, Edward Tsong, Chris Silvin, Patrick Soon‐Shiong et al. · 2021 · Journal for ImmunoTherapy of Cancer
Evolution of Molecular Targeted Cancer Therapy: Mechanisms of Drug Resistance and Novel Opportunities Identified by CRISPR-Cas9 Screening
Jue Hou, Zongsheng He, Tian Liu, Dongfeng Chen, Bin Wang, Qinglian Wen, Xi Zheng · 2022 · Frontiers in Oncology
SERS Multiplex Profiling of Melanoma Circulating Tumor Cells for Predicting the Response to Immune Checkpoint Blockade Therapy
Junrong Li, Alain Wuethrich, Zhen Zhang, Jing Wang, Lynlee L. Lin, Andreas Behren, Yuling Wang, Matt Trau · 2022 · Analytical Chemistry
A landscape of recent advances in lipid nanoparticles and their translational potential for the treatment of solid tumors
Radu Alexandru Paun, Sarah Jurchuk, Maryam Tabrizian · 2023 · Bioengineering & Translational Medicine
Advances and clinical applications of immune checkpoint inhibitors in hematological malignancies
Wenyue Sun, Shunfeng Hu, Xin Wang · 2024 · 癌症：英文版
Determinants of immunological evasion and immunocheckpoint inhibition response in non-small cell lung cancer: the genetic front
Maria Saigí, Juan J. Alburquerque-Béjar, Montse Sánchez‐Céspedes · 2019 · Oncogene
The roles of mutated SWI/SNF complexes in the initiation and development of hepatocellular carcinoma and its regulatory effect on the immune system: A review
Bo Hu, Jianzhen Lin, Xiaobo Yang, Xinting Sang · 2020 · Cell Proliferation
Breast cancer resistance mechanisms: challenges to immunotherapy
Ann Hanna, Justin Micah Balko · 2021 · Breast Cancer Research and Treatment
Somatic 9p24.1 alterations in HPV – head and neck squamous cancer dictate immune microenvironment and anti-PD-1 checkpoint inhibitor activity
Xin Zhao, Ezra E.W. Cohen, William N. William, Joy J. Bianchi, Jim P. Abraham, Daniel Magee, David B. Spetzler, Jorge Silvio Gutkind, Ludmil B. Alexandrov, Webster K. Cavenee et al. · 2022 · Proceedings of the National Academy of Sciences
Lipid Nanoparticle Delivery of Fas Plasmid Restores Fas Expression to Suppress Melanoma Growth In Vivo
Zeinab Y. Al Subeh, Dakota B. Poschel, Priscilla S. Redd, John David Klement, Alyssa D. Merting, Dafeng Yang, Megh Mehta, Huidong Shi, Yolonda Lorig Colson, Nicholas H. Oberlies et al. · 2022 · ACS Nano
Therapeutic potentials of medicinal plants and significance of computational tools in anti-cancer drug discovery
Kamoru Ademola Adedokun, Sikiru O. Imodoye, Ibrahim Olajide Bello, Abdul-Azeez A. Lanihun, Ibrahim Olajide Bello · 2023 · Elsevier eBooks
Dual IL-6 and CTLA-4 blockade regresses pancreatic tumors in a T cell– and CXCR3-dependent manner
Michael B. Ware, Maggie Phillips, Christopher William McQuinn, Mohammad Y. Zaidi, Hannah M. Knochelmann, Emily R. Greene, Brian Scott Robinson, Cameron J. Herting, Thomas A. Mace, Zhengjia Chen et al. · 2023 · JCI Insight
Natural killer cells in cancer immunotherapy
Danru Wang, LingYun Dou, Lihao Sui, Yiquan Xue, Sheng Xu · 2024 · MedComm
HLA ligandome analysis of primary chronic lymphocytic leukemia (CLL) cells under lenalidomide treatment confirms the suitability of lenalidomide for combination with T-cell-based immunotherapy
Annika Nelde, Daniel Johannes Kowalewski, Linus Backert, Heiko Schuster, Jan-Ole Werner, Reinhild Klein, Oliver Kohlbacher, Lothar Kanz, Helmut Rainer Salih, Hans‐Georg Rammensee et al. · 2017 · OncoImmunology